AURA NASDAQ
Boston, MA 02135
US
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Kratz Erica | A-Award | 100,885 | — | 2026-09-01 |
| Kratz Erica | A-Award | 199,115 | $7.43 | 2026-09-01 |
| Hopkins Janet Jill | A-Award | 58,850 | — | 2026-09-01 |
| Hopkins Janet Jill | A-Award | 116,150 | $7.43 | 2026-09-01 |
| Elazzouzi Amy | A-Award | 23,540 | — | 2026-09-01 |